Literature DB >> 17019714

Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer.

Antonio Ramos-Montoya1, Wai-Nang P Lee, Sara Bassilian, Shu Lim, Raisa V Trebukhina, Maria V Kazhyna, Carlos J Ciudad, Véronique Noé, Josep J Centelles, Marta Cascante.   

Abstract

The metabolic network of cancer cells confers adaptive mechanisms against many chemotherapeutic agents, but also presents critical constraints that make the cells vulnerable to perturbation of the network due to drug therapy. To identify these fragilities, combination therapies based on targeting the nucleic acid synthesis metabolic network at multiple points were tested. Results showed that cancer cells overcome single hit strategies through different metabolic network adaptations, demonstrating the robustness of cancer cell metabolism. Analysis of these adaptations also identified the maintenance of pentose phosphate cycle oxidative and nonoxidative balance to be critical for cancer cell survival and vulnerable to chemotherapeutic intervention. The vulnerability of cancer cells to the imbalance on pentose phosphate cycle was demonstrated by phenotypic phase plane analysis. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17019714     DOI: 10.1002/ijc.22227

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  52 in total

1.  Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle.

Authors:  Miriam Zanuy; Antonio Ramos-Montoya; Oscar Villacañas; Nuria Canela; Anibal Miranda; Esther Aguilar; Neus Agell; Oriol Bachs; Jaime Rubio-Martinez; Maria Dolors Pujol; Wai-Nang P Lee; Silvia Marin; Marta Cascante
Journal:  Metabolomics       Date:  2011-07-08       Impact factor: 4.290

Review 2.  The biochemistry, metabolism and inherited defects of the pentose phosphate pathway: a review.

Authors:  M M C Wamelink; E A Struys; C Jakobs
Journal:  J Inherit Metab Dis       Date:  2008-11-08       Impact factor: 4.982

3.  mTORC2 in the center of cancer metabolic reprogramming.

Authors:  Kenta Masui; Webster K Cavenee; Paul S Mischel
Journal:  Trends Endocrinol Metab       Date:  2014-05-21       Impact factor: 12.015

4.  Targeting thiamine-dependent enzymes for metabolic therapies in oral squamous cell carcinoma?

Authors:  M Grimm; B Calgéer; P Teriete; T Biegner; A Munz; S Reinert
Journal:  Clin Transl Oncol       Date:  2015-07-16       Impact factor: 3.405

5.  The in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanisms of action.

Authors:  Chih-Min Yang; Yi-Zih Liu; Jiunn-Wang Liao; Miao-Lin Hu
Journal:  Clin Exp Metastasis       Date:  2010-05-07       Impact factor: 5.150

6.  Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.

Authors:  Carmela Ricciardelli; Noor A Lokman; Sowmya Cheruvu; Izza A Tan; Miranda P Ween; Carmen E Pyragius; Andrew Ruszkiewicz; Peter Hoffmann; Martin K Oehler
Journal:  Clin Exp Metastasis       Date:  2015-04-21       Impact factor: 5.150

7.  Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation.

Authors:  Gema Alcarraz-Vizán; Joan Boren; Wai-Nang Paul Lee; Marta Cascante
Journal:  Metabolomics       Date:  2010-01-08       Impact factor: 4.290

Review 8.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

9.  Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis.

Authors:  Christina Wanka; Joachim P Steinbach; Johannes Rieger
Journal:  J Biol Chem       Date:  2012-08-10       Impact factor: 5.157

10.  The role of glucose metabolism and glucose-associated signalling in cancer.

Authors:  Rainer Wittig; Johannes F Coy
Journal:  Perspect Medicin Chem       Date:  2008-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.